Related Experiment Video
Updated: Aug 24, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
[Mechanisms of platelet activation and development of antiplatelet agents]
J P Cazenave1, C Gachet, F Lanza
1INSERM U 311, Strasbourg.
Platelets are activated by contact with vascular lesions in high flow arteries and are involved in the development of thrombosis, atherosclerosis and the complications of transluminal angioplasty. Hence platelets are one the targets of pharmacological intervention in the prevention and treatment of arterial thrombosis. Understanding of the mechanisms of activation of platelet has enabled the development of new antiplatelet agents and the improvement of their therapeutic usage. The most recent clinical drugs and those currently under development belong to two main families: antagonists of the membrane receptors of activation coupled to signal transducting G proteins which fix circulating stimuli such as ADP, thrombin and TXA2 and inhibitors of the binding of adhesive proteins such as fibrinogen to the GPIIb-IIIa integrin or of von Willebrand factor to the leucine-rich glycoprotein complex GPIb-V-IX.
Platelets are activated by contact with vascular lesions in high flow arteries and are involved in the development of thrombosis, atherosclerosis and the complications of transluminal angioplasty. Hence platelets are one the targets of pharmacological intervention in the prevention and treatment of arterial thrombosis. Understanding of the mechanisms of activation of platelet has enabled the development of new antiplatelet agents and the improvement of their therapeutic usage. The most recent clinical drugs and those currently under development belong to two main families: antagonists of the membrane receptors of activation coupled to signal transducting G proteins which fix circulating stimuli such as ADP, thrombin and TXA2 and inhibitors of the binding of adhesive proteins such as fibrinogen to the GPIIb-IIIa integrin or of von Willebrand factor to the leucine-rich glycoprotein complex GPIb-V-IX.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis

